Fosun International Reports 160.3% Profit Surge in 2026 Interim Results

Earnings
โดย PR Newswire·HK·Read original
Summary · why it matters

Fosun International held its 2026 interim results presentation in Hong Kong on August 28, marking its first such event in the city in six years. The company reported total revenue of RMB86.96 billion for the first half, with profit attributable to owners of the parent surging 160.3% year-on-year to RMB1.72 billion. Overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue. Chairman Guo Guangchang attributed the results to strategic adjustments, including "repairing the roof on a sunny day," and said the company will focus on industries where it holds competitive advantages. The four core companies—Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment—contributed 73.5% of total revenue. Technology innovation investment rose 16.7% to RMB4.2 billion. The board maintains a medium-term target of restoring annual profit to the RMB10 billion level.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 1 stocks
Fosun International Ltd
0656
▲ PositiveCapitalrelevance

Fosun International reported H1 2026 profit attributable to owners surging 160.3% year-on-year to RMB1.72 billion on revenue of RMB86.96 billion.

Others▲ · 2 stocks
© 2026 MarketDXNews